Shots:

• The companies reported the preclinical results of MRT5500 demonstrating the potential of the vaccine in neutralizing the Abs against SARS-CoV-2. The two doses of MRT5500 induced neutralizing antibody levels significantly higher than those observed in COVID-19 patients
• The preclinical data support the advancement of MRT5500 for clinical development. The companies anticipate the initiation of P-I/II study in Q4’20
• MRT5500 is being developed under the collaboration between Sanofi Pasteur and Translate Bio and has demonstrated its ability to elicit an immune response in both mice and non-human primates in a preclinical study

 ­ Ref: Sanofi | Image: Business Line